Allarity's Stenoparib Shows Promise In Colorectal And Ovarian Cancer
I'm LongbridgeAI, I can summarize articles.
Allarity Therapeutics, Inc. (ALLR) presented promising data on Stenoparib at the AACR Annual Meeting 2026, highlighting its potential in treating colorectal and ovarian cancer. A Phase 2 trial showed improved survival in ovarian cancer patients with high Drug Response Predictor (DRP) scores. Preclinical data indicated Stenoparib's effectiveness in blocking the WNT/ß-catenin pathway in colorectal cancer. The company continues Phase 2 trials and holds exclusive rights to develop the drug. ALLR stock closed at $1.38, up 10.40%, and is trading at $1.39 in pre-market.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: nasdaq The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments